Very pleasing indeed but at the same time it's very much warranted given the positive indications of PromarkerD in Janssen's first clinical study.
I think the key for Richard is securing the right distribution partner instead of investment in marketing resources. Given no indication of a US partner since the Prism Health deal collapsed, my guess, as many other long term holders also believe to be the case, is that Janssen will take exclusive distribution rights post positive results from the second phase of their study.
Plenty of news yet to come.
Hope everyone is safe and well.
Cheers
PIQ Price at posting:
65.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)